BOSTON SCIENTIFIC CORP

For the period ended Sep 30, 2024. Filed Nov 1, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 1, 2024

BSX$44.70+1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Cash Flows (Unaudited)

	Nine Months Ended September 30,
(in millions)	2024	2023
Net income (loss)	$1,284	$1,088
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities
Depreciation and amortization	921	883
Deferred and prepaid income taxes	10	(74)
Stock-based compensation expense	197	174
Goodwill and other intangible asset impairment charges	276	58
Net loss (gain) on investments and notes receivable	60	48
Contingent consideration net expense (benefit)	(4)	43
Inventory step-up amortization	—	6
Other, net	22	33
Increase (decrease) in operating assets and liabilities, excluding purchase accounting:
Trade accounts receivable	(261)	(164)
Inventories	(274)	(601)
Other assets	(109)	(43)
Accounts payable, accrued expenses and other liabilities	(142)	95
Cash provided by (used for) operating activities	1,979	1,546
Investing activities:
Purchases of property, plant and equipment and internal use software	(513)	(444)
Proceeds from sale of property, plant and equipment	1	4
Payments for acquisitions of businesses, net of cash acquired	(1,222)	(1,018)
Payments for investments and acquisitions of certain technologies, net of investment proceeds	(264)	(89)
Proceeds from royalty rights	16	23
Proceeds from settlements of hedge contracts	—	2
Cash provided by (used for) investing activities	(1,983)	(1,521)
Financing activities:
Payment of contingent consideration previously established in purchase accounting	(131)	(39)
Payments for royalty rights	(26)	(50)
Payments for finance leases	(25)	—
Payments on short-term borrowings	(504)	—
Proceeds from short-term borrowings, net of debt issuance costs	22	—
Net increase (decrease) in commercial paper	—	(4)
Proceeds from long-term borrowings, net of debt issuance costs	2,145	—
Cash dividends paid on preferred stock	—	(28)
Cash used to net share settle employee equity awards	(83)	(54)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans	202	165
Cash provided by (used for) financing activities	1,600	(10)
Effect of foreign exchange rates on cash	(2)	(8)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents	1,594	7
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period	1,055	1,126
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	$2,649	$1,132

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(SUPPLEMENTAL INFORMATION)

	Nine Months Ended September 30,
(in millions)	2024	2023
Supplemental Information
Stock-based compensation expense	$197	$174
Fair value of contingent consideration recorded in purchase accounting	29	—
Non-cash impact of transferred royalty rights	(16)	(23)

	As of September 30,
Reconciliation to amounts within the unaudited consolidated balance sheets:	2024	2023
Cash and cash equivalents	$2,502	$952
Restricted cash and restricted cash equivalents included in Other current assets	70	123
Restricted cash equivalents included in Other long-term assets	78	58
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	$2,649	$1,132

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.